Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918929 · ClinicalTrials.gov registry record · Phase 1
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 146
- Enrollment target
NCT02918929 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 146 participants.
The verdict
NCT02918929, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 146 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or without prediabetes or T2DM).
Interventions
- DRUG Placebo
- DRUG EDP 305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918929
The ClinicalTrials.gov registry entry for NCT02918929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02918929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918929 about?
NCT02918929 is a clinical study titled "A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD". This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or without prediabetes or T2D...
What is the current status of trial NCT02918929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 146 participants. The study started on 2016-09. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02918929?
The interventions under investigation include: Placebo (DRUG), EDP 305 (DRUG).
Who is sponsoring clinical trial NCT02918929?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.